Enliven Therapeutics (ELVN) Other Accumulated Expenses (2022 - 2026)

Enliven Therapeutics (ELVN) has 5 years of Other Accumulated Expenses data on file, last reported at $107000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 26.71% year-over-year to $107000.0; the trailing twelve-month figure through Mar 2026 stood at $107000.0 (down 26.71% YoY), and the FY2025 full-year result was $351000.0, up 72.06% from the prior year.
• Other Accumulated Expenses eased to $107000.0 in Q1 2026, from $351000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $548000.0 in Q1 2023 to a low of $63000.0 in Q2 2025.
• A 5-year average of $284285.7 and a median of $317000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• Peak annual rise in Other Accumulated Expenses reached 72.06% in 2025, while the deepest fall reached 78.35% in 2025.
• Tracing ELVN's Other Accumulated Expenses over 5 years: stood at $447000.0 in 2022, then slipped by 18.57% to $364000.0 in 2023, then sank by 43.96% to $204000.0 in 2024, then surged by 72.06% to $351000.0 in 2025, then plunged by 69.52% to $107000.0 in 2026.
• Business Quant data shows ELVN's Other Accumulated Expenses at $107000.0 in Q1 2026, $351000.0 in Q4 2025, and $86000.0 in Q3 2025.